Cited by 242Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 3 of the 4 references it cites were found in a registry or an index.

Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

Alexander, G. Caleb, Emerson, Scott, Kesselheim, Aaron S.·2021·JAMA

DOI 10.1001/jama.2021.3854

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1001/jama.2021.3854

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338
Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12617 · Cited by 22

Show all 4 references

Sorted by citations

Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In June 2021, aducanumab was approved by the FDA for medical use.(47,48) However, it is considered controversial due to the lack of sufficient evidence to support its efficacy.”
BackgroundMethod
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 315
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study
Cheung, C. Y.-L., Ran, A. R., Wang, S., Chan, V. T. T., Sham, K., Hilal, S., Venketasubramanian, N., Cheng, C., Sabanayagam, C., Tham, Y. C., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00169-8 · Cited by 272
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
Chouliaras, L., Thomas, A., Malpetti, M., Donaghy, P., Kane, J., Mak, E., Savulich, G., Prats-Sedano, M. A., Heslegrave, A. J., Zetterberg, H., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327788 · Cited by 199
Aducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R. L., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 201
Aducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“Thirdly, the close collaboration between the FDA and the sponsor could have impacted the objectivity of the FDA’s decision.(63,64) Furthermore, the AD ́s advocacy groups exerted much pressure on the FDA, defending that a marginal benefit of aducanumab would be significant to patients and caregivers.”
Background
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 190
Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 158
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0315 · Cited by 151
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 129
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno‐González, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 110
Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 104
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 98
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Ruan, D., & Sun, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 85
Mechanisms of ferroptosis in Alzheimer's disease and therapeutic effects of natural plant products: A review
Da, Z., Yang, K., Guo, H., Zeng, J., Wang, S., Xu, H., Ge, A., Zeng, L., Chen, S., & Ge, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114312 · Cited by 77
Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 77
Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
Kellar, D., Register, T. C., Lockhart, S. N., Aisen, P. S. S., Raman, R., Rissman, R. A., Brewer, J. B., & Craft, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05165-3 · Cited by 77
Multi-target-directed therapeutic strategies for Alzheimer's disease: controlling amyloid-β aggregation, metal ion homeostasis, and enzyme inhibition
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 78
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Lalli, G., Schott, J. M., Hardy, J., & Strooper, B. D. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114781 · Cited by 67
A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer’s Disease
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment
Anderson, T. S., Ayanian, J. Z., Souza, J., & Landon, B. E. (2021) · JAMA · doi:10.1001/jama.2021.15286 · Cited by 66
Aducanumab: The first targeted Alzheimer's therapy
Yang, P., & Sun, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01061 · Cited by 62
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 60
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 59
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C. E., Cho, H., & Ryu, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 58
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund‐Carlsen, P. F., Neve, R. L., Alavi, A. A., Herrup, K., Perry, G. L., Robakis, N. K. R. K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230099 · Cited by 56
Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: current and future perspective
Sharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 61
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck, L. M. (2021) · The Hastings Center Report · doi:10.1002/hast.1264 · Cited by 53
Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer’s disease via impacting on peripheral innate immune cells
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-03003-5 · Cited by 52
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
Li, V. O. K., Yang, H., Kaistha, T., Zhang, Q., Downey, J., Gozes, I., & Lam, J. C. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-85947-7 · Cited by 60
Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 50
The Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47
Self-citation
The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer’s disease
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 47
Stem cell therapy for Alzheimer’s disease: An overview of experimental models and reality
Qin, C., Wang, K., Zhang, L., & Bai, L. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12207 · Cited by 49
Microglia-Mediated Neurovascular Unit Dysfunction in Alzheimer’s Disease
Huang, W., Xia, Q., Zheng, F., Zhao, X. L., Ge, F., Xiao, J., Liu, Z., Shen, Y., Ye, K., Wang, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221064 · Cited by 47
Age- and sex-specific modifiable risk factor profiles of dementia: evidence from the UK Biobank
Chen, H., Cao, Y., Ma, Y., Xu, W., Zong, G., & Yuan, C. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-022-00952-8 · Cited by 46
Making the Case for Accelerated Withdrawal of Aducanumab
Whitehouse, P. J., Gandy, S., Saini, V., George, D. R., Larson, E. B., Alexander, G. C., Avorn, J., Brownlee, S., Camp, C. J., Chertkow, H. M., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220262 · Cited by 43
Self-citation
The functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer’s disease: crosstalk between autophagy and apoptosis
Qin, C., Bai, L., Li, Y., & Wang, K. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02765-8 · Cited by 44
Potential of Sorghum Polyphenols to Prevent and Treat Alzheimer’s Disease: A Review Article
Rezaee, N., Fernando, W. M. A. D. B., Hone, E., Sohrabi, H. R., Johnson, S. K., Gunzburg, S. T., & Martins, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.729949 · Cited by 46
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 42
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40
The role of endocannabinoid pathway in the neuropathology of Alzheimer’s disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer’s disease?
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 41
Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer’s disease and the role of glial cells
Gao, Y., Liu, J., Wang, J., Liu, Y., Zeng, L., Ge, W., & Ma, C. (2022) · Brain Pathology · doi:10.1111/bpa.13047 · Cited by 35
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 39
“Real world” eligibility for aducanumab
Canevelli, M., Rossi, P. D., Astrone, P., Consorti, E., Vanacore, N., & Cesari, M. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17390 · Cited by 36
A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer’s Disease
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.945091 · Cited by 39
Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Xing, X., Zhang, X., Wang, K., Wang, Z., Feng, Y., Li, X., Hua, Y., Zhang, L., & Dong, X. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01669-4 · Cited by 36
Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation
Shippy, D. C., & Ulland, T. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41897-6 · Cited by 35
Targeting sialylation to treat central nervous system diseases
Lünemann, J. D., von Gunten, S., & Neumann, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.09.002 · Cited by 38
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 35
Raising the bar for using surrogate endpoints in drug regulation and health technology assessment
Dawoud, D., Naci, H., Ciani, O., & Bujkiewicz, S. (2021) · BMJ · doi:10.1136/bmj.n2191 · Cited by 34
Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 35
The 2021 yearbook of Neurorestoratology
Sharma, H. S., Chopp, M., Chen, L., Sarnowska, A., Xue, M., Ao, Q., Siniscalco, D., Chen, L., Hawamdeh, Z. M., & Huang, H. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100008 · Cited by 31
On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer’s disease and Lewy body disease
Wei, H., Masurkar, A. V., & Razavian, N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1149036 · Cited by 30
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease
Tarawneh, R. M., Kasper, R. S., Sanford, J., Phuah, C., Hassenstab, J. J., & Cruchaga, C. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51685 · Cited by 29
Nanoparticles-based anti-aging treatment of Alzheimer’s disease
Chu, J., Ji, W., Zhuang, J., Gong, B., Chen, X., Cheng, W., Liang, W., Li, G., Gao, J., & Yin, Y. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094501 · Cited by 30
A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer’s Disease
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 28
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
D’Andrea, C., Cazzaniga, F. A., Bistaffa, E., Barucci, A., de Angelis, M., Banchelli, M., Farnesi, E., Polykretis, P., Marzi, C., Indaco, A., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00367-9 · Cited by 27
Approved drugs and natural products at clinical stages for treating Alzheimer’s disease
Ma, Y., Liu, S., Zhou, Q., Zhong-hua, L., ZHANG, Z., & Yu, B. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60606-0 · Cited by 27
Aducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 31
Aducanumab in Alzheimer’s Disease: A Critical Update
Ashique, S., Sirohi, E., Kumar, S., Rihan, M., Mishra, N., Bhatt, S., Gautam, R. K., Singh, S. K., Gupta, G., Chellappan, D. K., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230727103553 · Cited by 27
Nanoimmunomodulation of the Aβ-STING feedback machinery in microglia for Alzheimer’s disease treatment
Tian, L., Long, G., Zhu, S., Wang, Y., Xu, P., Liu, L., Yao, H., Fang, S., Chen, S., & Li, S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427257122 · Cited by 27
Therapeutic nanotechnologies for Alzheimer’s disease: A critical analysis of recent trends and findings
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 25
Making the Case for the Accelerated Withdrawal of Aducanumab
Whitehouse, P. J., & Saini, V. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220264 · Cited by 23
Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
Engelender, S., Stefanis, L., Oddo, S., & Bellucci, A. (2022) · Movement Disorders · doi:10.1002/mds.29058 · Cited by 23
Nanomodulators That Target Alzheimer’s Disease: A Review
Pradhan, N., & Jana, N. R. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04846 · Cited by 22
Prion protein and prion disease at a glance
Zhu, C., & Aguzzi, A. (2021) · Journal of Cell Science · doi:10.1242/jcs.245605 · Cited by 27
Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria
Togher, Z., Dolphin, H., Russell, C., Ryan, M., Kennelly, S., & O’Dowd, S. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5789 · Cited by 21
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer’s disease mouse model
Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., Strooper, B. D., & Morgan, B. P. (2024) · Brain · doi:10.1093/brain/awae278 · Cited by 23
Zinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 25
Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer’s Disease and Other Proteinopathies
Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 24
TAR DNA‐binding protein 43 oligomers in physiology and pathology
Lye, Y. S., & Chen, Y. (2022) · IUBMB Life · doi:10.1002/iub.2603 · Cited by 22
Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
Retinal thickness predicts the risk of cognitive decline over five years
Eppenberger, L. S., Li, C., Wong, D. W. K., Tan, B., Garhöfer, G., Hilal, S., Chong, E. J. Y., Toh, A. Q., Venketasubramanian, N., Chen, C., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01627-0 · Cited by 19
Frustrated peptide chains at the fibril tip control the kinetics of growth of amyloid-β fibrils
Xu, Y., Knapp, K., Le, K. N., Schafer, N. P., Safari, M. S., Davtyan, A., Wolynes, P. G., & Vekilov, P. G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110995118 · Cited by 19
Accelerated Approval of Aducanumab: Where Do We Stand Now?
Levy, H. B. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211050405 · Cited by 19
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
Paraskevas, G. P., & Kapaki, E. N. (2021) · Brain Sciences · doi:10.3390/brainsci11101258 · Cited by 18
A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17
Advancing Brain Research through Surface-Enhanced Raman Spectroscopy (SERS): Current Applications and Future Prospects
Elsheikh, S., Coles, N. P., Achadu, O. J., Filippou, P. S., & Khundakar, A. A. (2024) · Biosensors · doi:10.3390/bios14010033 · Cited by 18
The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer's disease
Sanders, O. D., Rajagopal, L., & Rajagopal, J. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.019 · Cited by 18
Effects of age on the relationship between sleep quality and cognitive performance: Findings from the Human Connectome Project-Aging cohort
Cohen, D. E., Kim, H., Levine, A., Devanand, D. P., Lee, S., & Goldberg, T. E. (2023) · International Psychogeriatrics · doi:10.1017/s1041610223000911 · Cited by 17
Utilizing deep learning to predict Alzheimer's disease and mild cognitive impairment with optical coherence tomography
Chua, J., Li, C., Antochi, F. A., Toma, E., Wong, D. W. K., Tan, B., Garhöfer, G., Hilal, S., Popa‐Cherecheanu, A., Chen, C., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70041 · Cited by 20
Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer’s Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress
Bajaj, S., Zameer, S., Jain, S., Yadav, V., & Vohora, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00699 · Cited by 17
Comparing Transcranial Direct Current Stimulation (tDCS) with Other Non-Invasive Brain Stimulation (NIBS) in the Treatment of Alzheimer’s Disease: A Literature Review
Wang, C. S., Chang, W. H., Yang, Y. K., & Cheng, K. (2023) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-023-00810-2 · Cited by 18
Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Vuić, B., Milos, T., Tudor, L., Perković, M. N., Konjevod, M., Erjavec, G. N., Farkaš, V., Uzun, S., Mimica, N., & Štrac, D. Š. (2023) · Genes · doi:10.3390/genes14112048 · Cited by 17
Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
Parums, D. V. (2021) · PubMed Central · doi:10.12659/msm.934077 · Cited by 17
Light-based gamma entrainment with novel invisible spectral flicker stimuli
Hansen, L. S., Carstensen, M. S., Henney, M. A., Nguyen, N. M., Thorning‐Schmidt, M. W., Broeng, J., Petersen, P. M., & Andersen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-75448-4 · Cited by 17
Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer’s disease model mice
Sadleir, K. R., Gómez, K., Edwards, A. E., Patel, A. J., Ley, M. L., Khatri, A. W., Guo, J., Mahesh, S., Watkins, E. A., Popović, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02888-1 · Cited by 18
The Structure of Cyclodecatriene Collinolactone, its Biosynthesis, and Semisynthetic Analogues: Effects of Monoastral Phenotype and Protection from Intracellular Oxidative Stress
Schmid, J. C., Frey, K., Scheiner, M., Garzón, J. F. G., Stafforst, L., Fricke, J., Schuppe, M., Schiewe, H., Zeeck, A., Weber, T., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106802 · Cited by 15

Authors: Alexander, G. C., Emerson, S., & Kesselheim, A. S.
Affiliations: Johns Hopkins University (US)
University of Washington (US)
Brigham and Women's Hospital (US)
ORCID: Alexander, G. Caleb
Emerson, Scott
Kesselheim, Aaron S.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2021-05-04
Volume: 325
Issue: 17
Pages: 1717
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2021.3854
OpenAlex: W3149600507
Cited by: 240
References: 4
Citations by year: 2026: 25 · 2025: 24 · 2024: 41 · 2023: 37 · 2022: 59 · 2021: 54
FWCI: 30.46
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, drug efficacy, clinical trials
MeSH terms: Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Treatment Failure, Drug Approval, Medical Futility, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks